BOSTON, Oct. 1, 2014 -- Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide, delivered continuously once or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback